Source: Pharamceutical Technology

BDSI: Collegium Pharmaceutical to purchase BioDelivery Sciences for $604m

BDSI's opioid product BELBUCA complements the pain product portfolio of Collegium. The post Collegium Pharmaceutical to purchase BioDelivery Sciences for $604m appeared first on Pharmaceutical Technology.

Read full article »
BDSI's Competitors | BDSI's News | BDSI's Financials
Stay up-to-date with the latest news on BDSI
Est. Annual Revenue
$100-500M
Est. Employees
100-250
Jeffrey A. Bailey's photo - CEO of BDSI

CEO

Jeffrey A. Bailey

CEO Approval Rating

87/100

Read more
Stay up-to-date with the latest news on BDSI